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Gain of Function of a p53 Hot Spot Mutation
in a Mouse Model of Li-Fraumeni Syndrome
opment (Malkin et al., 1990; Srivastava et al., 1990).
Individuals with p53 mutations are prone to early onset
tumor development and develop multiple tumors (Li and
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In contrast to other cancer syndromes, a wide varietyAdel K. El-Naggar,3 and Guillermina Lozano1,*
of tumor types are observed in LFS families; the most1Department of Molecular Genetics
common are sarcomas, breast cancers, leukemias,Section of Cancer Genetics
brain tumors, and adrenocortical carcinomas (Evans2Department of Experimental Therapeutics
and Lozano, 1997; Hwang et al., 2003). Most of the p533Department of Pathology
mutations in LFS are also missense mutations in theThe University of Texas M.D. Anderson Cancer
conserved regions of the p53DNAbinding domain, whileCenter and
a few are nonsense mutations that result in no p53 orThe University of Texas Graduate School
a truncated p53 protein.of Biomedical Sciences
Functional consequences of missense mutations ver-1515 Holcombe Boulevard
sus deletions of p53 have been extensively character-Houston, Texas 77030
ized in vitro (Sigal and Rotter, 2000). All p53 missense
mutations are loss-of-function mutations that mimic ab-
sence of p53 because of their inability to inhibit cellSummary
cycling or induce apoptosis. However, dominant-nega-
tive p53 mutants can inhibit the function of the normalIndividuals with Li-Fraumeni syndrome carry inherited
p53 protein, usually through protein-protein interactionsmutations in the p53 tumor suppressor gene and are
(Milner et al., 1991). The dominant-negative hypothesispredisposed to tumor development. To examine the
is strongly supported by the observations that manymechanistic nature of these p53 missense mutations,
mutant p53 proteins have an increased half-life (Finlaywe generated mice harboring a G-to-A substitution at
et al., 1988; Hinds et al., 1990; Slingerland et al., 1993)nucleotide 515 of p53 (p53/515A) corresponding to the
and that they oligomerize with wild-type p53, inhibitingp53R175H hot spot mutation in human cancers. Al-
its function (Farmer et al., 1992; Jeffrey et al., 1995;though p53/515Amice display a similar tumor spectrum
Milner et al., 1991; Sturzbecher et al., 1992). The forma-and survival curve asp53/mice, tumors fromp53/515A
tion of mixed wild-type and mutant p53 molecules con-mice metastasized with high frequency. Correspond-
verts wild-type p53 into themutant conformation in vitroingly, the embryonic fibroblasts from the p53515A/515A
(Milner et al., 1991). Gain-of-function mutations, on themutant mice displayed enhanced cell proliferation,
other hand, are those missense mutations in which mu-DNA synthesis, and transformation potential. The dis-
tant p53 has additional functions not seen in wild-typeruption of p63 and p73 in p53/ cells increased trans-
p53. For example, the p53R175H mutant, when overex-formation capacity and reinitiated DNA synthesis to
pressed in a nontransformed cell line lacking p53, yieldslevels observed in p53515A/515A cells. Additionally, p63
tumors in nude mice, while the parental cell line doesand p73 were functionally inactivated in p53515A cells.
not (Dittmer et al., 1993). Transgenic mice overexpress-These results provide in vivo validation for the gain-of-
ing the human p53R175H mutation in epithelial cellsfunction properties of certain p53 missense mutations
exhibit an increased susceptibility to chemical carcino-and suggest a mechanistic basis for these pheno-
genesis with shorter latency of tumor development astypes.
compared to mice lacking p53 (Li et al., 1998; Wang et
al., 1998a, 1998b).
Introduction While these experiments suggest both dominant-neg-
ative and gain-of-function phenotypes of p53 mutants,
The p53 tumor suppressor encodes a transcriptional they do not mimic the occurrence of p53 mutations in
regulator that controls cell cycle progression and apo- human tumors, since strong promoters drive expression
ptosis. In response to DNA damage or cellular stress, of the mutant p53 transgene to very high levels. The
p53 activity increases, initiating a cascade of events best experiments that assay these functions of p53 are
that block cell division. Thus, the p53 gene itself or the ones in which mutant p53 is not vastly overproduced.
p53 pathway is derailed in the development of most if Some of these experiments have been performed in
not all cancers. Somatic inactivation of p53 occurs in tissue culture using retroviral vectors to express wild-
over 50% of human tumors, the majority of which are type and/or mutant p53 in cells lacking endogenous p53
missense mutations in the DNA binding domain (Bartek (Chen et al., 1990). The introduction of another missense
et al., 1991; Greenblatt et al., 1994; Levine, 1993). mutation with gain-of-function properties, p53R273H,
Inheritedmutations in thep53 tumor suppressor occur yielded cells that are smaller, have a higher saturation
in individuals with Li-Fraumeni syndrome (LFS), a syn- density, and form colonies in soft agar as compared to
drome characterized by a predisposition to tumor devel- cells infected with a single copy of the wild-type p53
retrovirus. However, and perhaps more importantly, a
cell line containing one copy of each of the wild-type*Correspondence: gglozano@mdanderson.org
4These authors contributed equally to this work. and mutant p53 genes was indistinguishable from the
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cell line that expresses wild-type p53 alone. These data Results
indicate that, in the heterozygous state, wild-type p53
is dominant over mutant p53. These data contrast with Generation of p53515A Knockin Mice
To establish a LFS mouse model with a specific p53studies in murine ES cells in which the equivalent muta-
tion was introduced into the p53 locus. Upon exposure missense mutation, we generated mice with a targeted
mutation at the endogenous p53 locus using the cre-to  radiation, heterozygous ES cells show a dominant-
negative phenotype (de Vries et al., 2002). These oppos- loxP system (Figure 1A). We engineered an arg-to-his
substitution at amino acid 172 that corresponds to theing results suggest that, under different conditions, the
samep53mutation can or cannot function as a dominant hot spot mutation at arg 175 in humans. Southern blot
analysis was used to verify proper targeting of the en-negative. Importantly, these in vitro experiments cannot
determine the effect ofmutant p53 on survival and tumor dogenous p53 allele (Figure 1B). The neomycin gene
was removed from the targeted allele by crossing withspectrum in vivo. A mouse that contains a missense
mutation in one of the endogenous p53 genes would be transgenic mice expressing Cre recombinase (CMV-
cre). Sequence analysis of the entire coding region ininvaluable to understanding p53 missense mutations
in vivo. the p53 transcript from homozygous mutant mouse em-
bryos indicated no other changes (data not shown). ThisSeveral mechanisms have been identified to contrib-
ute to the p53 gain-of-function phenotype (Frazier et al., allele has been designated the p53515A to indicate the
G-to-A alteration at nucleotide 515.1998; Pugacheva et al., 2002; Sigal and Rotter, 2000).
Most attention has focused on the recently identified MEFs were generated from mice heterozygous and
homozygous for the p53515A mutation. The p53R172Hp53 family members p63 and p73 (Benard et al., 2003;
Soussi, 2003). Several p63 and p73 isoforms lacking the mutant protein was present at high levels in p53515A/515A
MEFs (Figure 1C). The levels of mutant p53 protein weretransactivation domain exist, called the TA isoforms,
that bind and inhibit the functions of full-length p63 and not high in p53/515A MEFs and could be due to the pres-
ence of the wild-type allele and its ability to activate thep73, respectively (Fillippovich et al., 2001; Ishimoto et
al., 2002; Stiewe et al., 2002; Yang et al., 1998). These mdm2 gene, which encodes a protein that degrades
both wild-type and mutant p53 (Asher et al., 2003; Iwa-isoforms also inhibit the function of p53. The TAp73
isoforms are upregulated in some tumors with wild-type kuma and Lozano, 2003).
p53, suggesting that they contribute to tumorigenesis
through inactivation of p53 (Concin et al., 2004; Zaika In Vivo Tumorigenesis
et al., 2002). Additionally, data using mice with deletions A cohort of p53mutant mice in the C57BL/6 background
of p63 and p73 indicate a cooperative nature of all p53 was generated to monitor tumor development and sur-
family members. p53-dependent apoptosis was nonex- vival. The survival curves comparing p53/, p53515A/515A,
istent in cells lacking p63 and p73 (Flores et al., 2002). and p53/515A mice were identical, perhaps owing to the
Thus, the interdependency of p63, p73, and p53 sug- rapid nature of tumor development (Figure 2A). The sur-
gests that disruption of any of these components crip- vival curves of p53/515A and p53/mice also overlapped
ples p53 tumor suppression function. The ability of mu- and showed no statistical difference (Figure 2B). No
tant p53 to bind and inhibit the function of p63 and p73 differences between survival of male and female mice
suggests that mutant p53 would be more detrimental were observed (data not shown). Our survival data for
than absence of p53. p53/ and p53/ mice were consistent with previously
To more accurately simulate the Li-Fraumeni syn- published data (Harvey et al., 1993a; Jacks et al., 1994).
drome and to examine the mechanistic nature of mis- The most common tumor types seen in mice with any
sensemutations on tumorigenesis in vivo, we generated of the above genotypes were lymphomas and sarcomas
and characterized a mouse model with an arg-to-his (Table 1). The majority of p53/ and p53515A/515A mice
alteration (a G-to-A substitution at nucleotide 515) at developed lymphomas (56% and 70%, respectively),
p53 amino acid 172, corresponding to the p53R175H with a smaller percentage developing sarcomas (40%
hot spot mutation in human cancers, by homologous and 29%, respectively). p53/ and p53/515A showed an
recombination at the endogenous locus. p53/515A mice increased frequency of sarcomas (56% and 53%, re-
developed tumors similarly to p53/ mice, with one spectively) with a concomitant decrease in lymphoma
major difference: osteosarcomas and carcinomas from development (32% and 31.5%, respectively). p53/ and
p53/515A mice metastasized to various organs with high p53/515A also developed carcinomas at low frequency
frequency. Thus, in vivo, mutant p53 has additional (12% and 15.5%), which are rare in p53/ and p53515A/515A
properties that allow metastasis. Mouse embryonic fi- mice. Thus, in aC57BL/6background, the comparisonof
broblasts (MEFs) from mice with one or two copies of p53 mutant (p53515A) and null alleles showed no differ-
the p53515A allele showed increased growth rates and ences in the kinds of tumors that these mice developed.
higher saturation densities. Moreover, these cells con- However, the tumor spectrum of heterozygous mice
tinued to undergo DNA synthesis under conditions in showed onemarked difference. The osteosarcomas and
which p53 heterozygous and null cells did not. Mecha- carcinomas in p53/515A mice metastasized (Table 1 and
nistically, p53R172H bound p63 andp73 inmouse tumor Figure 2C). Tumors and metastases from p53/515A mice
cell lines and downmodulation of p63 and p73 in p53 expressed high levels of p53 (Figure 2C). None of the
null MEFs increased transformation potential. Notably, p53/ heterozygousmice, in this and other cohorts that
these data indicate in vivo differences between loss of we have studied, exhibited metastasis (Liu et al., 2000,
p53 or presence of a p53mutation in tumor development 2004). Thus, while the survival of mice lacking p53 or
inheriting a missense mutation did not vary, p53/515Aand have significant implications for therapy.
p53 Mutant Mice
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Figure 1. Knockin Strategy and Character-
ization of the p53515A Allele
(A) The cre-loxP-mediated strategy was used
to generate the knockin allele. Mice with in-
sertion of the neomycin (neo) gene flanked
by loxP sites (triangles) and amissensemuta-
tion in exon 5 (asterisk) were generated and
mated with CMV-cre-expressing mice to de-
lete neo. The final product is a p53 gene with
a single loxP site in intron 4 and a single sub-
stitution at nucleotide 515.
(B) Southern blot analysis was performed on
mouse tail DNAs of the various genotypes
after digestion with EcoRI (RI). The banding
patterns for three different probes before and
after Cre recombination are shown.
(C) Western blot analysis of p53 protein
levels in MEFs of various genotypes. /,
p53/; /, p53/; /, p53/; /An,
p53/515Aneo; An/An, p53515Aneo/515Aneo; /A,
p53/515A; A/A, p53515A/515A.
mice developed osteosarcomas and carcinomas that tive, then mice null for mdm2 and p53/515A should be
born. Crosses between mdm2/ and mdm2/p53515A/515Ametastasized at high frequency.
Since the p53R172H mutant was not very stable in mice were performed. If the missense mutant has a
dominant-negative activity in this context, then we ex-p53/515AMEFs (see Figure 1C) but the equivalent mutant
is stable in human tumors, we performed immunohisto- pected 50% of the newborn mice to bemdm2/p53/515A.
This population of mice was not observed in ten off-chemical analysis on some of the p53/515A mouse tu-
mors. The results consistently showed stable p53 in spring born (data not shown), suggesting that the wild-
type p53 allele in p53/515A mice remained functionaltumor cells but not adjacent normal tissue (Figure 2C),
suggesting that other factors contribute to mutant p53 during embryogenesis. To examinep53-dependent apo-
ptosis in response to DNA damage, embryos at 13.5stability. One possible explanation for the increased lev-
els of p53 in tumors is the loss of thewild-type p53 allele. days gestation were irradiated and assayed for apopto-
sis in the region of the developing hypothalamus (FigureWe therefore examined tumors for lossof heterozygosity
(LOH) by SSCP (single-stranded conformation polymor- 2E). In this assay, p53 null mice showed no evidence of
apoptosis, while p53/ mice showed a high number ofphism) analysis using DNA isolated from tumors and
normal tissues in p53/515A mice by in situ laser capture apoptotic cells, although not quite as high as p53/
mice. Under the same conditions, p53/515Amice showedas we have previously described (Figure 2D) (Liu et al.,
2000). Only three of 13 tumors analyzed showed LOH, almost a complete absence of apoptosis, suggesting
that, in response to DNA damage, the p53R172Hmutantsuggesting that loss of the wild-type p53 allele is not a
prerequisite for increased mutant p53 levels. exerts a dominant-negative effect. These data and pub-
lished in vitro data suggest that, in response to DNA
damage, the mutant p53 can inhibit the function of wild-Analysis of p53R172H Function in the Presence
of Wild-Type p53 type p53 but not under all circumstances.
Other experiments performed to determine the role of
mutant p53 in inhibition ofwild-typep53 function include Proliferation Potential of MEFs
Previous studies of MEFs derived from p53 heterozy-crosses with themdm2 null allele and functional assays
in p53/515A mice. The mdm2 null mouse dies early in gous crosses showed that p53/ cells divided more
rapidly than p53/ and p53/ cells and that p53/embryogenesis, but this phenotype is completely res-
cued by deletion of p53 (Montes de Oca Luna et al., cells reached a higher saturation density than the other
genotypes (Harvey et al., 1993b). We therefore com-1995; Jones et al., 1995). This mouse thus provides an
in vivo assay to measure the functional significance of pared growth rates and saturation densities of cells with
the p53515A allele to determine if the presence of the p53p53 mutations (Iwakuma et al., 2004). We hypothesized
that, if p53R172H functioned as a true dominant nega- mutant protein bestowed a gain-of-function phenotype.
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864
Figure 2. Survival Curves of p53515A/515A, p53/515A, p53/, p53/, p53/, and p53/515A Mice
(A) Survival of p53/515A mice (n  24), p53515A/515A mice (n  32), and p53/ mice (n  23) with respect to number of days is plotted.
(B) Survival of p53/515A mice (n  83) and p53/ mice (n  40) with respect to number of days is plotted.
(C)Metastatic phenotype of osteosarcoma and adenocarcinoma. (i) Osteosarcomametastasis to the liver (arrows). (ii) p53 immunohistochemical
staining of adenocarcinoma of the lung and (iii) its metastatic lesion in the brain.
(D) LOH study of tumors with DNA isolated from paraffin-embedded tumors (T) and normal tissues (N) in p53/515A mice using laser-capture
microscopy. A representative result of SSCP with four different normal and tumor tissues is shown with control DNA (/, p53/; /A,
p53/515A; A/A, p53515A/515A).
(E) TUNEL analysis of sections through 13.5 day mouse embryos. Apoptosis is analyzed in the region of the developing hypothalamus of the
brain after IR.
The p53515A/515A and p53/515A MEFs initially did not show pected, and grew even faster than p53/ cells. By day
4, all cell lines reached saturation, but the p53515A/515A andany significant differences in growth rate compared to
the p53/ cell lines, but differences became apparent p53/515AMEFs reached amuch higher saturation density
compared to any of other genotypes. These data sug-at day 4 (Figure 3A). The p53515A/515A and p53/515A MEFs
grew more rapidly than p53/ and p53/ cells, as ex- gest that the p53515A mutation gives MEFs a growth ad-
p53 Mutant Mice
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Table 1. Tumor Spectrum and Metastatic Potential in p53 Mutant Mice
p53/ p53515A/515A p53/ p53/515A
Tumor Types (n  19) (n  33) (n  21) (n  65)
Lymphoma 56% 70% 32% 31.5%
Unclassified 12 (48%) 27 (61%) 8 (32%) 23 (29%)
Diffuse large cell 2 (8%) 4 (9%) 0% 2 (2.5%)
Sarcoma 40% 29% 56% 53%
Osteosarcoma 0% 0% 6 (24%) 22 (28%)a
Unclassified 6 (24%) 9 (20%) 7 (28%) 12 (15%)
Angiosarcoma 3 (12%) 4 (9%) 1 (4%) 8 (10%)
Rhabdomyosarcoma 1(4%) 0% 0% 0%
Carcinoma 4% 0% 12% 15.5%
Adenocarcinoma 1 (4%) 0% 1 (4%) 3 (4%)b
Squamous 0% 0% 2 (8%) 7 (9%)c
Poorly differentiated 0% 0% 0% 2 (2.5%)
Tumor totals 25 44 25 79
a23% metastasis (five out of 22).
b 67% metastasis (two out of three).
c 29% metastasis (two out of seven).
vantage allowing cells to bypass contact inhibition to a One mechanism involves the inhibition of activity of p53
familymembers p63 andp73 by interactionswithmutantgreater extent than p53/ MEFs. This supports a gain
of function for the p53 mutant allele. p53 (Di Como et al., 1999; Gaiddon et al., 2001; Strano
et al., 2002). Several p63 and p73 isoforms bind theSinceMEFs containingmutant p53 exhibited a growth
advantage, we decided to measure DNA synthesis upon p53R175H mutant protein, and the interaction inhibits
the transcriptional activity of p63 and p73 (Di Como etcontact inhibition. DNA synthesis was measured by [3H]
thymidine incorporation in MEFs of different genotypes al., 1999; Gaiddon et al., 2001). To examine the mecha-
nism of gain of function, we first asked whether endoge-at different time points after initial plating. p53/,
p53/, and p53/ cell lines showed identical DNA syn- nous murine p63 and p73 bound p53R172H. Tumor cell
lines from a lung adenocarcinoma (93-1), from an osteo-thesis profiles. DNA synthesis gradually declined over
time, the cells reached a quiescent state at day 6, and sarcoma (318-1), and from its metastasis (318-M) were
generated to examine the interaction of p63 and p73the cells did not reenter the cell cycle (Figure 3B). On
the other hand, DNA synthesis was always higher for with mutant p53. These tumors arose in p53/515A mice,
and the cell lines derived from these tumors had lostcells containingmutant p53. The p53515A/515A and p53/515A
cell lines showed significantly different DNA synthesis the wild-type p53 allele (data not shown). In 93-1 and
318-M cells, endogenous p63 clearly interacted withprofiles in this assay. While p53/, p53/, and p53/
cell lines never synthesizedDNAagain, cellswithmutant mutant p53 by coimmunoprecipitation and Western
analysis (Figure 4A). The interactions of p53 and p73p53 continued to synthesize DNA between days 6 and
10 (Figure 3B). Thus, again, the p53/515A and p53515A/515A were also clearly visible in all three cell lines. In the
reverse experiment, a p53-specific antibody coimmuno-mutant MEFs showed obvious differences from cells
lacking p53, providing additional evidence for a gain precipitated endogenous p63 and p73 (Figure 4A).
These data suggest that the p53R172H mutant bindsof function.
p63 and p73 in cell lines derived from tumors from
p53/515A mice. To determine if this interaction function-The p53R172H Mutant Increases Oncogenic
ally inactivated p63 and p73, we used siRNA to inhibitras-Induced Transformation of MEFs
expression of mutant p53 and assayed for transactiva-p53 missense mutations cooperate with activated ras
tion of p21. p73 and p63 have previously been shownin transformationof normal rat embryo fibroblasts (Hinds
to transactivate the p21 promoter through the p53-et al., 1989, 1990). To examine whether cells with an
responsive element (Di Como et al., 1999; Gaiddon etendogenous p53mutation exhibited an increased trans-
al., 2001; Kaghad et al., 1997; Strano et al., 2002; Yangformation potential, we infected p53/ and p53515A/515A
et al., 1998). 318-1 cells transfected with p53 siRNAscells with a retroviral vector containing a mutant Ha-
showed a dramatic decrease in mutant p53 protein lev-rasV12 cDNA and analyzed the focus-forming potential.
els (Figure 4B). To measure the activity of p63 and p73,p53515A/515A MEFs formed twice as many foci as p53/
318-1 cells that have lost the wild-type p53 allele (dataMEFs following ras transformation,while the vector con-
trols formed no foci in both genotypes (Figures 3C and not shown) were transfected with vector, murine p63,
3D). The size of the foci in the p53515A/515A mutant back- or HA-tagged p73 expression plasmids, with a p21
ground also appeared larger. These findings support a promoter luciferase plasmid, and with control or p53
role for the p53515A allele in cooperation with activated specific siRNAs. In all cases, samples with p53 siRNA
ras in transformation of cells, further supporting a gain- showed increased p21 promoter activity as compared
of-function hypothesis for the p53R172H mutant. to samples with control siRNA (Figure 4C). Both p63 and
p73 were able to activate the p21 promoter to a greater
extent in the absence of mutant p53. Experiments usingGain of Function via p63 and p73
Several mechanisms have been proposed to account bothp63 andp73 (at half theDNAconcentration each)
also showed increased p21 promoter activity upon inhi-for the gain-of-function effect observed for p53mutants.
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Figure 3. Proliferation and Transformation in MEFs
(A) To measure cell growth rates, MEFs of different genotypes were plated at day 0 and counted at indicated time points.
(B) Time course of DNA synthesis upon contact inhibition in MEFs as measured by incorporation of [3H] thymidine.
(C and D) The transformation potential of p53/ and p53515A/515A MEFs in cooperation with activated ras was measured using a focus-forming
assay. Low-passage MEFs were infected with a retroviral vector containing an activated Ha-rasV12 cDNA or vector control and diluted with
nontransfected cells before plating. Foci were counted after 14 days of growth.
bition of mutant p53. Even the addition of p53 siRNA tein levels by immunohistochemisty (Figure 5A) and
Western blot analyses (Figure 5B), while the levels ofalone showed a slight increase in p21 luciferase activity
(Figure 4C). We alsomeasured the ability of endogenous p63 and p73 remained high with control siRNAs.
To examine if the siRNAs specific for p63 and p73p63 and p73 to activate the endogenous p21 promoter.
In transfection experiments using 318-1 cells, the addi- could inhibit p63 and p73 expression in MEFs, we per-
formed Western blot (Figure 5C) and real-time RT-PCRtion of p53 siRNA inhibited the levels of endogenous
p53 and increased p21 mRNAs, as measured by real- analyses (Figure 5D). The data clearly show reduction
of p63 andp73protein levels. At themRNA level,p63andtime RT-PCR (Figure 4D). These data indicate functional
inactivation of p63 and p73 by the p53R172H mutant p73mRNAs were barely detectable when the respective
siRNAswere used. Thus, thep63 andp73 siRNAdramat-protein.
To determine the role of p63 and p73 in transforma- ically reduced the levels of endogenous mRNAs and
proteins in MEFs.tion, we downmodulated expression of p63 and p73 in
focus-forming assays with MEFs of different genotypes. Next, focus-forming assays were performed utilizing
these p63 and p73 siRNAs. MEFs were infected withFirst, to check the specificity of siRNAs, FLAG-tagged
p63 andmyc- taggedp73 expression constructswere activated ras, followed by transfection with siRNAs for
p63 and p73, or control siRNA. Control transfection ex-cotransfected with control siRNAs and siRNAs specific
for p63 or p73 into H1299 cells. The p63 and p73 siRNAs periments with or without siRNA showed no significant
effect on the number of foci that formed in p53/ andshowed almost complete inhibition of p63 and p73 pro-
p53 Mutant Mice
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Figure 4. p53R172H Coimmunoprecipitated
and Functionally Inactivated the TA Isoforms
of p63 and p73
(A) Coimmunoprecipitation experimentswere
performed on a p53/ (/) murine rhabdo-
mysarcoma cell line, a p53/515A lung adeno-
carcinoma cell line (93-1), a p53/515A osteo-
sarcoma cell line (318-1), and a p53/515A
osteosarcoma cell line from a metastasis
(318-M). All three tumor cell lines from
p53/515A mice had lost the wild-type p53 al-
lele. H1299 cells transfectedwith a p73plas-
mid (H1299/p73) were used as a control for
detection of p73.
(B) Control or p53 siRNAs were transfected
into 318-1 osteosarcoma cells derived from
a p53/515Amouse. After transfection,Western
blotting was performed using p53 and -actin-
specific antibodies.
(C) Luciferase assays were performed in
318-1 cells to measure p21 promoter activity.
A p21 reporter plasmid was cotransfected
with either a vector plasmid or p63 and/or
HA-tagged p73-encoding plasmids in the
presence of either control or p53-specific
siRNAs. Relative luciferase activities were
shown with standard deviations after normal-
ization with pRL-TK values. Western blot
analysis of p63 and p73 protein levels after
transfection was performed using p63 and
HA antibodies, respectively.
(D) Real-timeRT-PCRwas performed tomea-
sure the endogenous levels of p53 and p21
mRNAs after transfection with siRNA for p53
in 318-1 cells.
p53515A/515A MEFs (Figures 5E and 5F). As in previous 6A). p53/ and p53/ MEFs did not incorporate [3H]
thymidine beyond day 6, while p53515A/515A MEFs contin-experiments (Figures 3C and 3D), p53515A/515A MEFs
showed a 2-fold increase in the number of foci as com- ued to synthesize DNA (Figure 6A). p63 and p73 siRNA
transfection experiments in p53515A/515A MEFs resulted inpared to p53/ MEFs. In contrast, p53/ MEFs trans-
fected with siRNAs specific for p63 and p73 showed a no change in the DNA synthesis profile, supporting the
possibility that p63 and p73 are already inhibited in thissignificant increase in the number of foci that formed.
The foci number in p53/ cells increased by approxi- cell line (Figure 6B). However, in p53/ MEFs, p63 and
p73 siRNA had a significant effect. Inhibition of p63 andmately 2-fold, similar to the number seen in p53515A/515A
MEFs and in p53515A/515A MEFs transfected with control p73 resulted in continued DNA synthesis beyond day 6,
similar to p53515A/515A MEFs (Figures 6C and 6D). ThesesiRNAs. In addition, p53515A/515A MEFs showed no notice-
able difference in foci number when transfected with findings provided further evidence that the p63 and/or
p73 pathways are inhibited in p53515A/515A MEFs.both p63 and p73 siRNAs, suggesting the increased
number of foci is caused by the inhibition of p63 and/
or p73 in p53515A/515A MEFs. Discussion
In this study, we have generated a knockin allele of aInhibition of p63 and p73 in p53/ MEFs Reinitiates
DNA Synthesis common p53 mutation in a more faithful reproduction
of the LFS. Several important observations arose fromTo examine the importance of p63 and p73 in the gain-
of-function phenotype, we exploited another difference these studies. First, the osteosarcomas and carcinomas
from p53/515A mice metastasize, as in humans, to thebetween mutant and wild-type cells. Cells with one or
two copies of the p53 null allele cease to replicate DNA lymph nodes, lung, liver, and brain, while tumors from
p53/ mice do not (Donehower et al., 1992; Jacks etafter short-term culture (Figure 3B), while cells with one
or two copies of the p53515A allele reinitiate DNA synthe- al., 1994). These data are supported by a metastatic
phenotype seen in tumors from mice with a hypomor-sis. We therefore transfected siRNAs for p63 and p73,
or control siRNA into low passageMEFs, andmonitored phic allele of the same mutation (Liu et al., 2000). Since
all mice in this study are in the same genetic back-DNA synthesis with time. The control siRNA-transfected
cells yielded similar results as previous experiments ground, C57BL/6, the data clearly indicate a gain-of-
function phenotype for this p53 mutation in vivo. In thewithout transfection of siRNAs (compare Figures 3B and
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Figure 5. siRNAs Specific for Murine p63 and p73 Enhance Transformation Potential of p53/ but Not p53515A/515A MEFs
(A) FLAG-tagged p63 or myc-tagged p73 expression plasmids were transfected with control siRNAs or specific siRNAs into H1299 cells,
and cells were stained with anti-FLAG or anti-myc antibody to detect p63 or p73, respectively.
(B) Western blotting was performed using anti-p63 or anti-myc antibodies after FLAG-tagged p63 or myc-tagged p73 cotransfection
with siRNAs.
(C) Western blot analysis of the levels of p63 and p73 expressed after transfection with p63 and p73 siRNA. C, control; /, p53/; A/A,
p53515A/515A.
(D) Real-time RT-PCR was used to measure the levels of p63 and p73 mRNA after transfection with p63 and p73 siRNA, respectively.
(E) The transformation potential of p53/ and p53515A/515A MEFs in cooperation with Ha-rasV12 was measured following transfection of control
and p63/p73 siRNAs.
(F) Foci were counted after 14 days of growth and graphed. p53/ and p53515A/515A MEFs were infected with vector (lanes 1 and 5), Ha-rasV12
(lanes 2 and 6), Ha-rasV12 and control siRNA (lanes 3 and 7), and Ha-rasV12and p63/p73 siRNA (lanes 4 and 8). Multiple plates were counted
from duplicate experiments.
accompanying paper, Olive et al. (2004 [this issue of mice (Harvey et al., 1993c; Donehower et al., 1995). Thus,
not only do p53mutant alleles elicit a gain of function butCell]) also find a gain-of-function phenotype in mice
inheriting the same mutation. However, in the 129S4/ they alsomanifest different tumor incidences in different
strains of mice.SvJae strain, they also see a different tumor spectrum
in mutant heterozygous mice, as compared to p53/ To mechanistically examine the gain-of-function phe-
p53 Mutant Mice
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Figure 6. siRNAs Specific for Murine p63 and p73 Allowed p53/ MEFs to Reinitiate DNA Synthesis
(A) [3H] thymidine incorporation was measured at different times after plating in p53/, p53/, and p53515A/515A MEFs transfected with con-
trol siRNA.
(B) Comparison of DNA synthesis profiles for p53515A/515A MEFs with control and p63/p73-specific siRNAs.
(C) Comparison of DNA synthesis profiles for p53/ MEFs with control and p63/p73-specific siRNA.
(D) p53/ MEFs transfected with p63/p73 siRNAs resulted in DNA synthesis trends that were very similar to p53515A/515A MEFs.
notype, we developed tissue culture-based assays us- Jacks (submitted) have generated p53/ p63/ and
p53/ p73/ mice to analyze the role of p63 and p73ing MEFs of various genotypes. p53515A/515A MEFs exhibit
twice the transforming potential as compared to p53/ in tumorigenesis. Notably, these mice develop tumors
that metastasize. Thus, the combined in vitro and in vivoMEFs. These differences are overcome by eliminating
p63 and p73 in p53/ cells. Experiments designed to data indicate that mutant p53 binds and inhibits the
function of p63 and p73 and that haploinsufficiency formeasure DNA synthesis show the same phenotype.
Whereas early passage p53 null MEFs cease DNA syn- either p63 or p73 reproduces the metastatic phenotype
in p53/ mice.thesis, reinitiation of DNA synthesis occurs upon down-
modulation of p63 and p73, similar to p53515A/515A MEFs. The generation of p53/515A mice and cells has allowed
adetailed characterization of the effects of heterozygos-These data indicate that downmodulation of p63 and
p73 in cells in culture increased transformation potential ity on wild-type and mutant p53 function. Importantly,
the p53R172H protein in p53/515A mice is not stable butbut do not exclude the possibility that other factors
might also contribute. To correlate the tissue culture becomes stable in tumors. In the developing embryo,
the absence of mdm2 resulted in a lethal phenotype indata with tumorigenesis in vivo, we showed the interac-
tion of endogenous p63 and p73 proteins with mutant p53/515A mice, suggesting that wild-type p53 is func-
tional. Since the mdm2 null phenotype is rescued byp53 in three independent tumor cell lines derived from
p53/515A mice that had lost the wild-type p53 allele. loss of p53, the lack of dominant-negative activity of
p53R172H in embryogenesis is clear. The inability of theMoreover, functional inactivation of p63 and p73 was
observed in the same tumor cell lines. Our data indicate mutant p53 to function in the presence of a wild-type
allele suggests that p53R172H cannot inactivate p63that mutant tumor cell lines producing p53R172H from
a single copy of the gene lack functional p63 and p73. and p73 in embryogenesis and is supported by the ab-
sence of lethal phenotypes, as seen with loss of p63However, while we have observed the interaction of p63
and p73 with mutant p53 and have identified a role of and p73 (Yang et al., 1999, 2000). Thus, in a heterozy-
gous mouse in an in vivo situation, mutant p53 does notp63 and p73 in a gain-of-function phenotype in MEFs
and tumor cell lines, we have no direct evidence that drive wild-type p53 into a mutant conformation as it
does in vitro (Milner et al., 1991). This predicts that otherp63 and p73 play a role in metastasis in vivo. Flores and
Cell
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pregnant CD1 female recipients. The resulting chimeras were matedalterationsmust occur to stabilize mutant p53 in tumors.
with C57BL/6 females. Mice with the targeted allele were crossedThis may explain the lack of difference in survival be-
with CMV-cre transgenic mice (also in the C57BL/6 background) totween p53/ and p53/515A mice, since stabilization of
remove the loxP-flanked neomycin cassette. Mice carrying the
p53 requires other changes for tumorigenesis. This p53515A allele were crossed with C57BL/6 mice for more than four
change could be as simple as loss of wild-type p53, as generations until the genetic background was greater than 90%
C57BL/6 to establish the cohort for a tumor study. Genotyping wasseen in tumor cell lines from p53/515A mice. However,
performed by polymerase chain reaction (PCR) analysis using prim-the majority of the tumors (ten out of 13) retain the wild-
ers previously described surrounding the loxP sites (Liu et al., 2004).type p53 allele. Additionally, posttranslational modifica-
tions may be required to stabilize p53. In response to
DNA damage, p53 is modified by phosphorylation and Cell Culture
Cell lines were maintained in Dulbecco’s modified Eagle’s mediumacetylation, although the importance of these modifica-
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Atlantations on p53 stability and function is controversial (Ap-
Biologicals) and penicillin (100 IU/ml)/streptomycin (100 g/ml).pella and Anderson, 2001).
MEFs were generated by crossing mice of the appropriate geno-
The possibility that posttranslational modifications types and collecting embryos at 13.5 dpc. For cell growth rates and
are needed to stabilize p53R172H is supported by DNA saturation densities, 5 	 105 MEFs were plated on 100 mm tissue
damage experiments. In response to DNA damage, p53- culture dishes and counted as needed. To monitor DNA synthesis,
1–3 	 106 cells were plated on 60 mm culture dishes in 4 ml DMEMdependent apoptosis is vastly reduced in the embryonic
with 20% FBS and left unperturbed. At the indicated days, MEFsbrain of p53/515A mice, suggesting that, in this scenario,
were incubated with 1 mCi [3H] thymidine for 2 hr before measuringthe p53R172H mutant inactivates wild-type p53.
the radioactivity incorporated into cells using liquid scintillation
p53R172Hmay also be binding and inactivating p63 and counting.
p73, a possibility that is supported by the observation
that p63 or p73 null embryos also lack a p53-dependent
Focus-Forming Assaysapoptotic response (Flores et al., 2002). These data sug-
Low-passageMEFswere infected with a retroviral vector containinggest that posttranslational modifications may be re-
an activated Ha-rasV12 cDNA and a puromycin resistance gene. Two
quired for mutant p53 to inhibit the function of wild-type days after infection, puromycin was added to select a pool of cells
p53 andmembers of its family. Thus, further understand- expressingHa-rasV12. Following selection, 2000 puromycin-resistant
cells were mixed with 998,000 noninfected cells of the same geno-ing of the regulation ofmutant p53 stability is imperative.
type and plated. On day 14, the plates were fixed and stained withThis study showed in vivo differences between p53/
crystal violet in 70% ethanol, and foci were counted. Transfectionand p53/515A in that tumors from p53/515A mice metasta-
with siRNAs was performed after viral infection and selection.sized. Another mouse heterozygous for an arg-to-pro
mutation at p53 amino acid 172, a less common muta-
Tumor Samplestion identified in human tumors, shows delayed tumor
A cohort of mice wasmonitored for signs of illness or obvious tumoronset and no metastasis (Liu et al., 2004). Since these
burden. Moribund mice were sacrificed, and the major organs andmice are otherwise genetically identical, the data indi-
tumors were fixed with 4% formalin in PBS. Tissues were paraffin
cate in vivo differences between mutant p53 alleles in embedded and sectioned at 10 m. All sections were stained with
tumorigenesis. Thus, identification of the type of p53 hematoxylin and eosin prior to pathological analysis. Immunohisto-
mutation in human patients may be important to deter- chemical analysis was performed as previously described (Evans et
al., 2001). For LOH study, DNAwas isolated fromparaffin-embeddedmine the course of therapy. Many reports suggest that
tumors and normal tissues from p53/515Amice by a pathologist usingthe presence of p53 mutations in tumors correlated with
laser-capture microscopy and PCR amplified for SSCP analysis asresistance to chemotherapy and worse prognosis as
previously described (Liu et al., 2000).
compared to tumors lacking p53 mutations (Iacopetta,
2003; Lai et al., 2000; Powell et al., 2000; Skaug et al.,
Design of siRNAs Specific for Murine p53, p63, and p732000). Other reports show the opposite (Bataille et al.,
siRNAs specific for murine p53, p63, and p73 were designed and2003; Lane and Hupp, 2003; Zhivotovsky et al., 1999).
confirmed for uniqueness using the BLASTN program. The target
It is enticing to speculate that the kind of p53 mutation sequence for p53 is 5
-AAGTCTGTTATGTGCACGTAC-3
 (spanning
that occurs and the posttranslational events that modify amino acids 117–123), for p63 is 5
-AAGAGACCGGAAGGCAGA
the mutant may be important in response to chemother- TGA-3
 (spanning amino acids 134–141), and for p73 is 5
-AAGGCAG
AGTGTGGTTGTGCC-3
 (spanning amino acids 224231).apy. Clearly, typing of p53 mutations should be per-
formed in human tumors to determine the relevance of
our mouse models to human disease. Transfections and Luciferase Assay
For transfection experiments, lipofectamine reagent was used ac-
cording to themanufacturer’s protocol (Invitrogen). DNAand siRNAsExperimental Procedures
weremixed in a 5:1 (g) ratio. ForWestern blotting and immunostain-
ing, cells were harvested 24–42 hr after transfection. For DNA syn-Generation of p53515A Knockin Mice
The targeting vector was generated by cloning a loxP-flanked thesis and focus-forming assays, cells were used 48 hr after trans-
fection. For luciferase assays, cells were seeded at 70% confluencyPGKneo cassette into the second AccI site of intron 4 of a p53
genomic fragment. An arginine-to-histidine substitution (CGC to 1 day before transfection. The p21 reporter plasmid (pGLp21Luc)
(0.7 g) was used with an internal control, 0.15 g of pRL-TK (Pro-CAC) at codon 172 was performed by site-directed mutagenesis.
The resulting construct was then cloned into a vector containing a mega). Either p63 or p73 expressing plasmids (0.3 g) were co-
transfected with these luciferase plasmids. When both p63 and p73thymidine kinase (TK) cassette. The entire targeting construct was
sequence verified (data not shown) and linearized with NotI. Tar- were cotransfected, 0.15 g of each plasmid was used. In addition,
2l of 20Mcontrol siRNA (Scramble II, Dharmacon) orp53-specificgeting vector (25 g) was electroporated into AB-1 embryonic stem
(ES) cells. DNA from G418-resistant FIAU-sensitive ES colonies was siRNA was also added to the transfection. The dual reporter lucifer-
ase assay system (Promega) was used to measure p21 promotersubjected to Southern blot analysis. Two targeted ES cell clones
were injected into C57BL/6 blastocysts and transferred into pseudo- activity according to manufacturer’s instruction.
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Real-Time RT-PCR quently up-regulated in ovarian cancer. Evidence for their role as
epigenetic p53 inhibitors in vivo. Cancer Res. 64, 2449–2460.mRNAs were harvested using RNeasy kit (Qiagen). Reverse tran-
scriptase reactions were performed using the First-Strand cDNA de Vries, A., Flores, E.R., Miranda, B., Hsieh, H.M., van Oostrom,
Synthesis Kit (Amersham Bioscience). Real-time PCR was per- C.T., Sage, J., and Jacks, T. (2002). Targeted point mutations of p53
formed to manufacturer’s specifications (Applied Biosystems). The lead to dominant-negative inhibition of wild-type p53 function. Proc.
following primers were used: p21, CCTGACAGATTTCTATCACTCCA Natl. Acad. Sci. USA 99, 2948–2953.
and CAGGCAGCGTATATCAGGAG; p53, ACATGACGGAGGTCGT
Di Como, C.J., Gaiddon, C., and Prives, C. (1999). p73 function isGAGA and TTTCCTTCCACCCGGATAAG; p63, AAAGAACGGCGAT
inhibited by tumor-derived p53 mutants in mammalian cells. Mol.GGTACGA and GGTACAGCAGCTCATCATCTGG; p73, AGAGCATG
Cell. Biol. 19, 1438–1449.TGACCGACATTGTT and TTCTACACGGATGAGGTGGCT; GAPDH,
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M.,TCACCACCATGGAGAAGGC and GCTAAGCAGTTGGTGGTGCA.
Finlay, C., and Levine, A.J. (1993). Gain of function mutations in p53.Primer sequences were obtained using the Primer Express program
Nat. Genet. 4, 42–46.and checked for gene specificity by BLASTN. Relative mRNA ex-
pression was normalized to the value of GAPDH for each reaction. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Mont-
gomery, C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient
Western Blot and Coimmunoprecipitation Analyses for p53 are developmentally normal but susceptible to spontaneous
Protein extracts (100 g) from MEFs were run on polyacrylamide tumours. Nature 356, 215–221.
gels, transferred to Hybond P membranes (Amersham Pharmacia), Donehower, L.A., Harvey, M., Vogel, H., McArthur, M.J., Montgom-
and probed with antibodies for p53 (CM5, Novacastra; FL393, Santa ery, C.A., Jr., Park, S.H., Thompson, T., Ford, R.J., and Bradley,
Cruz) and -actin (Sigma). The secondary antibody used was horse- A. (1995). Effects of genetic background on tumorigenesis in p53-
radish peroxidase conjugated (Amersham). Signal detection was deficient mice. Mol. Carcinog. 14, 16–22.
carried out with an electrochemiluminescence kit (Pierce). For coim-
Evans, S.C., and Lozano, G. (1997). The Li-Fraumeni syndrome: anmunoprecipitation experiments, cells were lysed on ice in a buffer
inherited susceptibility to cancer. Mol. Med. Today 3, 390–395.of 100 mM Tris-Cl (pH 8.0), 100 mM NaCl, 1% NP40, and proteinase
inhibitors. Lysate (1.5 mg) was precleared with protein A agarose Evans, S.C., Viswanathan, M., Grier, J.D., Narayana, M., El-Naggar,
beads. The following antibodies were added according to themanu- A.K., and Lozano, G. (2001). An alternatively spliced HDM2 product
facturer’s recommendations: p53, CM5 and FL-393; p63, Ab-1 (Neo- increases p53 activity by inhibiting HDM2. Oncogene 20, 4041–4049.
markers); and p73, Ab-2 (Oncogene Research). Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and
Prives, C. (1992). Wild-type p53 activates transcription in vitro. Na-
Analysis of Apoptosis in 13.5 dpc Embryonic Brains ture 358, 83–86.
The in vivo TUNEL assay was performed as previously described
Fillippovich, I., Sorokina, N., Gatei, M., Haupt, Y., Hobson, K., Moal-(Liu et al., 2004).
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